INTEGRIS-IPF Clinical Trial

Clinical Trial

INTEGRIS-IPF, a Phase 2a clinical trial studying PLN-74809, an oral investigational medicine for the potential treatment of idiopathic pulmonary fibrosis, has completed enrollment. In July 2022, Pliant presented positive data from this multinational trial evaluating PLN-74809 at once-daily doses of 40 mg, 80 mg, 160 mg or placebo for 12 weeks.

Based upon these data, Pliant is planning for interactions with regulatory authorities to discuss the late-stage development of PLN-74809 in IPF.

For more information

To learn more about our trials, please visit or contact us at